In April 2025, Radiopharm dosed the first patient in the U.S. Phase 2b imaging study of 18F-RAD101. The multicenter, open-label, single arm Phase 2b clinical trial is evaluating the diagnostic ...

A first-of-its-kind solution for women's arousal in a proprietary topical formulation demonstrated to work where women need it most Targeted to be available by prescription in the fourth quarter of 20 ...

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.

The rising occurrence of dysmenorrhea, along with greater awareness and advancements in diagnosis, is driving substantial growth in the dysmenorrhea treatment market. With more women pursuing medical ...

SNMMI 2025 radium-223-treated patients, REASSURE study, metastatic castration-resistant prostate cancer (mCRPC), ALSYMPCA trial, safety of radium-223 in patients with mCRPC.

Rooter, solid Q1 results, and 50% upside potential underscore its long-term appeal. See why CHE stock is a buy.

Objectives To analyse patient profiles, transportation patterns and time delays in ischaemic time and door-to-balloon (DTB) time and evaluate the effect of these delays on in-hospital mortality among ...

There isn't a one-size-fits-all treatment for perimenopause symptoms, but you can start by tackling your most bothersome ...

Some married females will be serious about going the family way. Minor professionalism-related issues will be there. The productivity may not be as per the expectation and the seniors may raise their ...

Background Restarting direct oral anticoagulants (DOACs) after a serious bleeding event in patients with atrial fibrillation ...